7096 — StemCell Institute Income Statement

0.000.00%

Last trade - 00:00

HealthcareSmall CapFalling Star

Annual income statement for StemCell Institute, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,676	1,410	1,782	2,091	2,481
Cost of Revenue
Gross Profit	1,133	924	1,111	1,336	1,576
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,294	1,324	1,555	1,815	2,066
Operating Profit	382	85.9	227	276	415
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	383	91.4	213	279	441
Provision for Income Taxes
Net Income After Taxes	277	62.4	134	198	311
Net Income Before Extraordinary Items
Net Income	277	62.4	134	198	311
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	277	62.4	134	198	311
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	27.1	6.15	13.1	20.8	30.2
Dividends per Share